Researchers have identified a pattern of longer overall survival in patients with stage IV rectal SCC than among patients with stage IV colon SCC.

For patients with metastatic primary pNETs, resection is associated with improved survival outcomes but also linked to perioperative complications.

Younger patients with neuroendocrine tumors have worse symptom burden health-related quality of life than older patients, researchers report.

The Food and Drug Administration (FDA) has approved Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory ...

Phase 3 ARENSENS clinical trial results were presented at JADPRO 2025, indicating darolutamide plus ADT improved rPFS in prostate cancer.

Adding immunotherapy to chemotherapy can improve survival in patients with metastatic, poorly differentiated GEP-NECs, data suggest.

A phase 1/2 study showed durable remission, manageable safety in pts with R/R follicular lymphoma who received fixed-duration mosunetuzumab.in.

Researchers presented efficacy and ongoing safety data from MonumenTAL-1, a phase 1/2 study assessing talquetamab in patients with multiple myeloma.

CAPTEM (capecitabine and temozolomide) provided a high rate of disease control in patients with typical and atypical lung ...

New research suggests that, among patients with neuroendocrine tumors, primary tumor sites differ by race, and overall survival outcomes differ by tumor site and gender.

Results of CheckMate 67T, a phase 3 noninferiority study comparing subcutaneous and intravenous nivolumab formulations in RCC, were presented at JADPRO 2025.

A retrospective study found an association between elevated ALC and CAR+ T-cell counts and development of neurologic events in patients with r/r MM.